A

Asymchem Laboratories Tianjin Co Ltd
SZSE:002821

Watchlist Manager
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Watchlist
Price: 77.7 CNY 0.86%
Market Cap: 28.6B CNY
Have any thoughts about
Asymchem Laboratories Tianjin Co Ltd?
Write Note

Asymchem Laboratories Tianjin Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Asymchem Laboratories Tianjin Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Short-Term Debt
ÂĄ74.9m
CAGR 3-Years
N/A
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Short-Term Debt
ÂĄ1.1B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
60%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Short-Term Debt
ÂĄ249m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
37%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Short-Term Debt
ÂĄ4.1B
CAGR 3-Years
10%
CAGR 5-Years
20%
CAGR 10-Years
21%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Short-Term Debt
ÂĄ318.9m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Asymchem Laboratories Tianjin Co Ltd
Glance View

Market Cap
28.7B CNY
Industry
Pharmaceuticals

In the bustling industrial landscape of Tianjin, Asymchem Laboratories stands as a beacon of innovation and precision in the biopharmaceutical world. Founded with a vision to harmonize the intricate processes of pharmaceutical development, Asymchem has evolved into a powerhouse of Contract Development and Manufacturing Organization (CDMO) services. The company provides end-to-end solutions in the pharmaceutical sector, specializing in the synthesis and manufacturing of small molecule active pharmaceutical ingredients (APIs). Their sophisticated laboratories and state-of-the-art production facilities serve a global clientele, demanding not only high-quality standards but also a seamless integration of complex processes—from drug discovery through commercialization. Asymchem's business model thrives on the symbiosis between its technical expertise and the ever-growing demand for innovative pharmaceuticals. They offer a comprehensive suite of services including research and development, process optimization, and full-scale commercial production. The company's revenue streams are tied to its ability to win long-term contracts with major pharmaceutical companies, focusing on creating custom-tailored solutions that expedite the drug development timeline while ensuring compliance with stringent regulatory standards. By aligning their operations with the needs of the biopharmaceutical industry, Asymchem secures its positioning as a key player, propelling forward the possibilities of modern medicine while ensuring sustainable growth in the competitive pharmaceutical manufacturing sector.

Intrinsic Value
101.28 CNY
Undervaluation 23%
Intrinsic Value
Price
A

See Also

What is Asymchem Laboratories Tianjin Co Ltd's Short-Term Debt?
Short-Term Debt
74.9m CNY

Based on the financial report for Sep 30, 2024, Asymchem Laboratories Tianjin Co Ltd's Short-Term Debt amounts to 74.9m CNY.

What is Asymchem Laboratories Tianjin Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
20%

Back to Top